[
    [
        {
            "time": "2021-12-03",
            "original_text": "恒瑞医药9个药品纳入国家医保目录",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "国家医保",
                    "药品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "恒瑞医药9个药品纳入国家医保目录",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "新版国家医保目录公布，恒瑞已上市8款创新药全部进入医保",
            "features": {
                "keywords": [
                    "新版医保",
                    "恒瑞医药",
                    "创新药"
                ],
                "sentiment_score": 0.95,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "新版国家医保目录公布，恒瑞已上市8款创新药全部进入医保",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "70万一针“天价药”纳入医保，多家上市公司公告来了",
            "features": {
                "keywords": [
                    "天价药",
                    "医保",
                    "上市公司"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "70万一针“天价药”纳入医保，多家上市公司公告来了",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-03",
            "original_text": "国家医保谈判结果出炉：“天价罕见病药”成功入选，国产“网红”PD-1成大赢家",
            "features": {
                "keywords": [
                    "医保谈判",
                    "天价罕见病药",
                    "国产",
                    "PD-1"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "国家医保谈判结果出炉：“天价罕见病药”成功入选，国产“网红”PD-1成大赢家",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-02",
            "original_text": "A股融资融券日报：两融余额减少72.45亿元",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额减少72.45亿元",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-12-02",
            "original_text": "暴跌61%！FDA拒批万春药业普那布林上市，波及恒瑞医药",
            "features": {
                "keywords": [
                    "暴跌",
                    "FDA",
                    "万春药业",
                    "恒瑞医药"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "暴跌61%！FDA拒批万春药业普那布林上市，波及恒瑞医药",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        }
    ]
]